ANPCF
CelLBxHealth plc
Set alert
- YTD
- -41.67%
- 1 year
- -60.80%
- Open
- 0.0098
- Prev close
- 0.0098
- Mkt cap
- 11.14M
- Vol
- 10.00K
- Avg vol
- 156
- EPS
- -0.05
- P/E
- 0.00
More statistics
- Low
- 0.0098
- High
- 0.0098
News
1 week ago proactiveinvestors.com
CelLBxHealth looking up as it bolsters commercial pipeline
CelLBxHealth PLC (AIM:CLBX, FRA:DWV) told investors it is targeting revenues of £3 million to £4 million in 2027, potentially more than doubling its expected 2026 turnover, as new pharmaceutical…
1 week ago proactiveinvestors.com
CelLBxHealth lands contract with Swiss biotech for clinical study
CelLBxHealth PLC (AIM:CLBX, FRA:DWV) has secured an agreement with a Swiss biotechnology company to support a radiopharmaceutical clinical study, extending the use of its circulating tumour cell…
2 weeks ago proactiveinvestors.com
Cellbxhealth signs new statement of work with US pharma company
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), which develops technology to collect tumour cells from blood, has signed a new statement of work worth around $65,000 with an existing US pharmaceutical…
2 months ago proactiveinvestors.co.uk
CelLBxHealth's blood test spots hard-to-detect cells from brain tumours
An independent study has found that tumour cells circulating in the blood of patients with the most aggressive form of brain cancer can be captured and analysed using technology made by CelLBxHealth…
2 months ago proactiveinvestors.co.uk
CelLBxHealth study detects drug targets on cancer cells rivals would miss
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the liquid biopsy company, said an independent study had shown its Parsortix system can detect the biological targets used by a fast-growing class of cancer…
3 months ago proactiveinvestors.co.uk
CelLBxHealth moves from cutting to converting
The interim figures mark the point where CelLBxHealth PLC (AIM:CLBX, FRA:DWV) stops being a restructuring story and starts being a commercial one, says a note from Cavendish. The heavy lifting is…
3 months ago proactiveinvestors.co.uk
CelLBxHealth builds £3.5m weighted pipeline as revenue growth target held
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed cancer diagnostics company, said its commercially weighted pipeline had built to £3.5 million, supported by rising engagement from pharmaceutical…
3 months ago proactiveinvestors.co.uk
CelLBxHealth reaffirms revenue guidance
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the cancer diagnostics company, has told shareholders it remains on track to deliver revenues of at least £2.1 million for 2026 as it searches for a new chief…
4 months ago proactiveinvestors.co.uk
Cavendish backs CelLBxHealth turnaround with buy rating, 4p target
Cavendish remains bullish on CelLBxHealth PLC (AIM:CLBX, FRA:DWV) with a 'buy' rating and 4p price target in the wake of its prelims earlier. The AIM-listed biotech has completed a strategic reset…
4 months ago proactiveinvestors.co.uk
CelLBxHealth guides for 50% revenue growth as partnership pipeline swells
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell diagnostics company, expects revenues of at least £2.1 million in 2026, representing growth of at least 50% from last year's £1.4…
5 months ago proactiveinvestors.co.uk
CelLBxHealth strikes US clinical collaboration with AdventHealth cancer studies
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed circulating tumour cell (CTC) diagnostics company, has secured a collaboration with AdventHealth, one of the largest faith-based health systems in…
8 months ago proactiveinvestors.com
Enbridge reports record 2025 earnings, reaffirms 2026 guidance
Enbridge Inc (TSX:ENB) on Friday reported record financial results for 2025, driven by higher earnings across its operations, and reaffirmed its 2026...
8 months ago proactiveinvestors.co.uk
CelLBxHealth shares rise 3% as company continues to focus on cost base
Shares in CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) rose 3% to 1.08p on Thursday after the company announced it would discontinue its United States Food and Drug Administration establishment…
8 months ago proactiveinvestors.co.uk
CelLBxHealth drops FDA device listing to cut costs and refocus on revenue growth
CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) has decided to discontinue maintenance of its United States Food and Drug Administration establishment licence and device listing for the Parsortix…
8 months ago proactiveinvestors.com
CelLBxHealth drops FDA device listing to cut costs and refocus on revenue growth
CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) has decided to discontinue maintenance of its United States Food and Drug Administration establishment...
9 months ago proactiveinvestors.com
Nasdaq, Dow Jones little changed as TSMC settles tech jitters
1:15pm: Market movers Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable...
9 months ago proactiveinvestors.co.uk
CelLBxHealth backed for rebound by broker
CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) is a recovery story with asymmetric upside. In a note published on Friday, Cavendish reiterated its 4.0p price target, implying more than 300% upside…
9 months ago proactiveinvestors.co.uk
CelLBxHealth enters 2026 with strong pipeline
CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) said it is entering 2026 with a sharpened strategy and a focus on turning a £12.6 million sales pipeline into revenues, adding that its balance sheet…
9 months ago proactiveinvestors.com
CelLBxHealth enters 2026 with strong pipeline
CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) said it is entering 2026 with a sharpened strategy and a focus on turning a £12.6 million sales pipeline...
9 months ago proactiveinvestors.com
Gold prices will keep rising on macroeconomics and geopolitical risk - UBS
UBS expects gold to keep rising after hitting fresh record highs. The broker said bullion has already climbed around 7% this year after a near 65% gain in...